학술논문
Circulating long non-coding RNA GAS5 (growth arrest-specific transcript 5) as a complement marker for the detection of malignant mesothelioma using liquid biopsies
Document Type
Academic Journal
Author
Weber, Daniel G.; Casjens, Swaantje; Brik, Alexander; Raiko, Irina; Lehnert, Martin; Taeger, Dirk; Gleichenhagen, Jan; Kollmeier, Jens; Bauer, Torsten T.; Brüning, Thomas; Johnen, Georg; Burek, Katarzyna; Dumont, Bettina; Hagemeyer, Olaf; Heimann, Heike; Kobek, Monika; Lechtenfeld, Claudia; Meier, Swetlana; Naumann, Simone; Nöllenheidt, Christoph; Pesch, Beate; Putzke, Simone; Rihs, Hans-Peter; Rozynek, Peter; Schonefeld, Sandra; Szafranski, Katja; Töpfer, Carmen; Wichert, Katharina; Wiethege, Thorsten; Zilch-Schöneweis, Sandra
Source
Biomarker Research. May 13, 2020, Vol. 8 Issue 1
Subject
Language
English
ISSN
2050-7771
Abstract
Author(s): Daniel G. Weber[sup.1], Swaantje Casjens[sup.1], Alexander Brik[sup.1], Irina Raiko[sup.1], Martin Lehnert[sup.1], Dirk Taeger[sup.1], Jan Gleichenhagen[sup.1], Jens Kollmeier[sup.2], Torsten T. Bauer[sup.2], Thomas Brüning[sup.1], Georg Johnen[sup.1], Katarzyna Burek, Bettina Dumont, Olaf [...]
Background For the detection of malignant mesothelioma additional markers are needed besides the established panel consisting of calretinin and mesothelin. The aim of this study was the identification and verification of long non-coding RNAs (lncRNAs) as complementing circulating markers. Methods Candidate lncRNAs were identified in silico using previously published RNA expression profiles and verified using quantitative PCR (qPCR) in mesothelioma cell lines as well as human plasma samples from mesothelioma patients and asbestos-exposed controls. Results GAS5 (growth arrest-specific transcript 5) as a single marker is marked by a low sensitivity of 14%, but the combination of GAS5 with calretinin and mesothelin increased the panel's sensitivity from 64 to 73% at a predefined specificity of 97%. Circulating GAS5 is not affected by pleurectomy before blood collection, age, or smoking status. Conclusions GAS5 is verified as an appropriate circulating marker for the supplement of calretinin and mesothelin to detect malignant mesothelioma. Although the sensitivity of GAS5 is too low for the use as a single marker, the addition of GAS5 as a third marker improves the performance of the established marker panel. The benefit of GAS5 for the detection of malignant mesothelioma at early stages needs to be validated in a prospective study. Keywords: Biomarker, Blood, Cancer, Circulating, Early detection, Liquid biopsy, lncRNA, Marker, Mesothelioma, Plasma, qPCR, Screening
Background For the detection of malignant mesothelioma additional markers are needed besides the established panel consisting of calretinin and mesothelin. The aim of this study was the identification and verification of long non-coding RNAs (lncRNAs) as complementing circulating markers. Methods Candidate lncRNAs were identified in silico using previously published RNA expression profiles and verified using quantitative PCR (qPCR) in mesothelioma cell lines as well as human plasma samples from mesothelioma patients and asbestos-exposed controls. Results GAS5 (growth arrest-specific transcript 5) as a single marker is marked by a low sensitivity of 14%, but the combination of GAS5 with calretinin and mesothelin increased the panel's sensitivity from 64 to 73% at a predefined specificity of 97%. Circulating GAS5 is not affected by pleurectomy before blood collection, age, or smoking status. Conclusions GAS5 is verified as an appropriate circulating marker for the supplement of calretinin and mesothelin to detect malignant mesothelioma. Although the sensitivity of GAS5 is too low for the use as a single marker, the addition of GAS5 as a third marker improves the performance of the established marker panel. The benefit of GAS5 for the detection of malignant mesothelioma at early stages needs to be validated in a prospective study. Keywords: Biomarker, Blood, Cancer, Circulating, Early detection, Liquid biopsy, lncRNA, Marker, Mesothelioma, Plasma, qPCR, Screening